ES2642204T3 - Compuestos derivados de arilpirrolopiridina como inhibidores de LRRK2 - Google Patents
Compuestos derivados de arilpirrolopiridina como inhibidores de LRRK2 Download PDFInfo
- Publication number
- ES2642204T3 ES2642204T3 ES14720062.0T ES14720062T ES2642204T3 ES 2642204 T3 ES2642204 T3 ES 2642204T3 ES 14720062 T ES14720062 T ES 14720062T ES 2642204 T3 ES2642204 T3 ES 2642204T3
- Authority
- ES
- Spain
- Prior art keywords
- pyridine
- carbonitrile
- pyrrolo
- amino
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 150000001875 compounds Chemical class 0.000 title claims description 114
- 229940124786 LRRK2 inhibitor Drugs 0.000 title description 9
- -1 Morpholin-4-ylmethyl Chemical group 0.000 claims description 43
- 208000018737 Parkinson disease Diseases 0.000 claims description 35
- 125000001072 heteroaryl group Chemical group 0.000 claims description 28
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 27
- 229910052757 nitrogen Inorganic materials 0.000 claims description 26
- 150000003839 salts Chemical class 0.000 claims description 21
- 238000011282 treatment Methods 0.000 claims description 21
- 201000010099 disease Diseases 0.000 claims description 20
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 19
- 125000003118 aryl group Chemical group 0.000 claims description 18
- 125000005842 heteroatom Chemical group 0.000 claims description 16
- 230000035772 mutation Effects 0.000 claims description 16
- 150000003973 alkyl amines Chemical class 0.000 claims description 14
- 125000005262 alkoxyamine group Chemical group 0.000 claims description 13
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 13
- 125000003545 alkoxy group Chemical group 0.000 claims description 11
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims description 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 8
- 229910052717 sulfur Inorganic materials 0.000 claims description 8
- 208000035475 disorder Diseases 0.000 claims description 7
- 102000009784 Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 Human genes 0.000 claims description 6
- 108010020246 Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 Proteins 0.000 claims description 6
- 229910052736 halogen Inorganic materials 0.000 claims description 6
- 150000002367 halogens Chemical class 0.000 claims description 6
- ZZDGQQQSEKEUFO-UHFFFAOYSA-N 4-(3-methoxyphenyl)-1h-pyrrolo[2,3-b]pyridine-3-carbonitrile Chemical compound COC1=CC=CC(C=2C=3C(C#N)=CNC=3N=CC=2)=C1 ZZDGQQQSEKEUFO-UHFFFAOYSA-N 0.000 claims description 4
- IQBHNQCIUDQGPV-UHFFFAOYSA-N 4-(3-methylphenyl)-6-[(1-methylpyrazol-3-yl)amino]-1h-pyrrolo[2,3-b]pyridine-3-carbonitrile Chemical compound CC1=CC=CC(C=2C=3C(C#N)=CNC=3N=C(NC3=NN(C)C=C3)C=2)=C1 IQBHNQCIUDQGPV-UHFFFAOYSA-N 0.000 claims description 4
- PHGSTYLIFXUHNG-UHFFFAOYSA-N 4-[3-ethyl-4-(morpholin-4-ylmethyl)phenyl]-1h-pyrrolo[2,3-b]pyridine-3-carbonitrile Chemical compound CCC1=CC(C=2C=3C(C#N)=CNC=3N=CC=2)=CC=C1CN1CCOCC1 PHGSTYLIFXUHNG-UHFFFAOYSA-N 0.000 claims description 4
- ANIYDVYTJUHGSI-UHFFFAOYSA-N 4-[3-methyl-4-(morpholin-4-ylmethyl)phenyl]-6-[(1-methylpyrazol-3-yl)amino]-1h-pyrrolo[2,3-b]pyridine-3-carbonitrile Chemical compound CC1=CC(C=2C=3C(C#N)=CNC=3N=C(NC3=NN(C)C=C3)C=2)=CC=C1CN1CCOCC1 ANIYDVYTJUHGSI-UHFFFAOYSA-N 0.000 claims description 4
- BBKNRIAOOMXTKD-UHFFFAOYSA-N 4-phenyl-6-(pyridin-2-ylamino)-1H-pyrrolo[2,3-b]pyridine-3-carbonitrile Chemical compound N#Cc1c[nH]c2nc(Nc3ccccn3)cc(-c3ccccc3)c12 BBKNRIAOOMXTKD-UHFFFAOYSA-N 0.000 claims description 4
- XXZAJGJUAVDOEK-UHFFFAOYSA-N 6-[(1-methylpyrazol-3-yl)amino]-4-phenyl-1h-pyrrolo[2,3-b]pyridine-3-carbonitrile Chemical compound CN1C=CC(NC=2N=C3NC=C(C3=C(C=3C=CC=CC=3)C=2)C#N)=N1 XXZAJGJUAVDOEK-UHFFFAOYSA-N 0.000 claims description 4
- CQKZFKDVSPPXNC-UHFFFAOYSA-N 6-[(1-methylpyrazol-4-yl)amino]-4-phenyl-1h-pyrrolo[2,3-b]pyridine-3-carbonitrile Chemical compound C1=NN(C)C=C1NC1=CC(C=2C=CC=CC=2)=C(C(=CN2)C#N)C2=N1 CQKZFKDVSPPXNC-UHFFFAOYSA-N 0.000 claims description 4
- KWTGXMXCSXFSJX-UHFFFAOYSA-N 6-amino-4-(3-methylphenyl)-1h-pyrrolo[2,3-b]pyridine-3-carbonitrile Chemical compound CC1=CC=CC(C=2C=3C(C#N)=CNC=3N=C(N)C=2)=C1 KWTGXMXCSXFSJX-UHFFFAOYSA-N 0.000 claims description 4
- QMJRKPFSSQENNG-UHFFFAOYSA-N 6-amino-4-phenyl-1h-pyrrolo[2,3-b]pyridine-3-carbonitrile Chemical compound C=12C(C#N)=CNC2=NC(N)=CC=1C1=CC=CC=C1 QMJRKPFSSQENNG-UHFFFAOYSA-N 0.000 claims description 4
- 201000002832 Lewy body dementia Diseases 0.000 claims description 4
- 102200092175 rs7308720 Human genes 0.000 claims description 4
- KBHSVDKRLSYHJD-UHFFFAOYSA-N 4-(3-ethylphenyl)-1h-pyrrolo[2,3-b]pyridine-3-carbonitrile Chemical compound CCC1=CC=CC(C=2C=3C(C#N)=CNC=3N=CC=2)=C1 KBHSVDKRLSYHJD-UHFFFAOYSA-N 0.000 claims description 3
- ANPOAAOWVMMUTG-UHFFFAOYSA-N 4-(3-methylphenyl)-1h-pyrrolo[2,3-b]pyridine-3-carbonitrile Chemical compound CC1=CC=CC(C=2C=3C(C#N)=CNC=3N=CC=2)=C1 ANPOAAOWVMMUTG-UHFFFAOYSA-N 0.000 claims description 3
- GRGHLILILXVPIC-UHFFFAOYSA-N 4-(5-methylpyridin-3-yl)-6-[[1-methyl-4-(trifluoromethyl)pyrazol-3-yl]amino]-1h-pyrrolo[2,3-b]pyridine-3-carbonitrile Chemical compound CC1=CN=CC(C=2C=3C(C#N)=CNC=3N=C(NC=3C(=CN(C)N=3)C(F)(F)F)C=2)=C1 GRGHLILILXVPIC-UHFFFAOYSA-N 0.000 claims description 3
- IHVBFXAXYRLAMA-UHFFFAOYSA-N 4-(6-methylpyridin-2-yl)-6-[[1-methyl-4-(trifluoromethyl)pyrazol-3-yl]amino]-1h-pyrrolo[2,3-b]pyridine-3-carbonitrile Chemical compound CC1=CC=CC(C=2C=3C(C#N)=CNC=3N=C(NC=3C(=CN(C)N=3)C(F)(F)F)C=2)=N1 IHVBFXAXYRLAMA-UHFFFAOYSA-N 0.000 claims description 3
- VPDXOKREAVLVLN-UHFFFAOYSA-N 4-[3-methoxy-4-(morpholin-4-ylmethyl)phenyl]-1h-pyrrolo[2,3-b]pyridine-3-carbonitrile Chemical compound COC1=CC(C=2C=3C(C#N)=CNC=3N=CC=2)=CC=C1CN1CCOCC1 VPDXOKREAVLVLN-UHFFFAOYSA-N 0.000 claims description 3
- WDGYKJMMIOPTCD-UHFFFAOYSA-N 4-[3-methyl-4-(morpholin-4-ylmethyl)phenyl]-1h-pyrrolo[2,3-b]pyridine-3-carbonitrile Chemical compound CC1=CC(C=2C=3C(C#N)=CNC=3N=CC=2)=CC=C1CN1CCOCC1 WDGYKJMMIOPTCD-UHFFFAOYSA-N 0.000 claims description 3
- NQDGORODAYJETA-UHFFFAOYSA-N 4-[4-(morpholin-4-ylmethyl)phenyl]-1h-pyrrolo[2,3-b]pyridine-3-carbonitrile Chemical compound C=12C(C#N)=CNC2=NC=CC=1C(C=C1)=CC=C1CN1CCOCC1 NQDGORODAYJETA-UHFFFAOYSA-N 0.000 claims description 3
- BHEBICBPOTVZFO-UHFFFAOYSA-N 4-thiophen-3-yl-1h-pyrrolo[2,3-b]pyridine-3-carbonitrile Chemical compound C=12C(C#N)=CNC2=NC=CC=1C=1C=CSC=1 BHEBICBPOTVZFO-UHFFFAOYSA-N 0.000 claims description 3
- BGDVHDMLORIBJR-UHFFFAOYSA-N 6-[(1,4-dimethylpyrazol-3-yl)amino]-4-(6-methylpyridin-2-yl)-1h-pyrrolo[2,3-b]pyridine-3-carbonitrile Chemical compound CC1=CN(C)N=C1NC1=CC(C=2N=C(C)C=CC=2)=C(C(=CN2)C#N)C2=N1 BGDVHDMLORIBJR-UHFFFAOYSA-N 0.000 claims description 3
- YDCKUJIRXIKLNS-UHFFFAOYSA-N 6-[(1-methylpyrazol-3-yl)amino]-4-(5-methylpyridin-3-yl)-1h-pyrrolo[2,3-b]pyridine-3-carbonitrile Chemical compound CC1=CN=CC(C=2C=3C(C#N)=CNC=3N=C(NC3=NN(C)C=C3)C=2)=C1 YDCKUJIRXIKLNS-UHFFFAOYSA-N 0.000 claims description 3
- CBDJPXSHMIUPAJ-UHFFFAOYSA-N 6-[(4-chloro-1-methylpyrazol-3-yl)amino]-4-(4-methylpyridin-2-yl)-1h-pyrrolo[2,3-b]pyridine-3-carbonitrile Chemical compound CC1=CC=NC(C=2C=3C(C#N)=CNC=3N=C(NC=3C(=CN(C)N=3)Cl)C=2)=C1 CBDJPXSHMIUPAJ-UHFFFAOYSA-N 0.000 claims description 3
- 208000015114 central nervous system disease Diseases 0.000 claims description 3
- VYEFDAQRXKQMPZ-UHFFFAOYSA-N 4-(2,4-dimethylphenyl)-1h-pyrrolo[2,3-b]pyridine-3-carbonitrile Chemical compound CC1=CC(C)=CC=C1C1=CC=NC2=C1C(C#N)=CN2 VYEFDAQRXKQMPZ-UHFFFAOYSA-N 0.000 claims description 2
- NSJGIUMXLVXGPU-UHFFFAOYSA-N 4-(3-hydroxyphenyl)-1h-pyrrolo[2,3-b]pyridine-3-carbonitrile Chemical compound OC1=CC=CC(C=2C=3C(C#N)=CNC=3N=CC=2)=C1 NSJGIUMXLVXGPU-UHFFFAOYSA-N 0.000 claims description 2
- WRQMDDJZRIRGLV-UHFFFAOYSA-N 4-phenyl-1H-pyrrolo[2,3-b]pyridine-3-carbonitrile Chemical compound N#Cc1c[nH]c2nccc(-c3ccccc3)c12 WRQMDDJZRIRGLV-UHFFFAOYSA-N 0.000 claims description 2
- VXEOEBNYHYCSIR-UHFFFAOYSA-N 6-[(1,4-dimethylpyrazol-3-yl)amino]-4-(2-methylpyridin-4-yl)-1h-pyrrolo[2,3-b]pyridine-3-carbonitrile Chemical compound CC1=CN(C)N=C1NC1=CC(C=2C=C(C)N=CC=2)=C(C(=CN2)C#N)C2=N1 VXEOEBNYHYCSIR-UHFFFAOYSA-N 0.000 claims description 2
- 101100294102 Caenorhabditis elegans nhr-2 gene Proteins 0.000 claims description 2
- 206010067889 Dementia with Lewy bodies Diseases 0.000 claims description 2
- DXASQZJWWGZNSF-UHFFFAOYSA-N n,n-dimethylmethanamine;sulfur trioxide Chemical group CN(C)C.O=S(=O)=O DXASQZJWWGZNSF-UHFFFAOYSA-N 0.000 claims description 2
- 102200058742 rs121909568 Human genes 0.000 claims description 2
- 102220577899 Leucine-rich repeat serine/threonine-protein kinase 2_G2019S_mutation Human genes 0.000 claims 2
- 102220577984 Leucine-rich repeat serine/threonine-protein kinase 2_I2020T_mutation Human genes 0.000 claims 2
- 102220578200 Leucine-rich repeat serine/threonine-protein kinase 2_G2385R_mutation Human genes 0.000 claims 1
- 102220577920 Leucine-rich repeat serine/threonine-protein kinase 2_M1646T_mutation Human genes 0.000 claims 1
- 102220596657 Leucine-rich repeat serine/threonine-protein kinase 2_R1398H_mutation Human genes 0.000 claims 1
- 102220596654 Leucine-rich repeat serine/threonine-protein kinase 2_R1441C_mutation Human genes 0.000 claims 1
- 102220579336 Leucine-rich repeat serine/threonine-protein kinase 2_R1441G_mutation Human genes 0.000 claims 1
- 102220596659 Leucine-rich repeat serine/threonine-protein kinase 2_R1441H_mutation Human genes 0.000 claims 1
- 102220577921 Leucine-rich repeat serine/threonine-protein kinase 2_R1628P_mutation Human genes 0.000 claims 1
- 102220577885 Leucine-rich repeat serine/threonine-protein kinase 2_S1647T_mutation Human genes 0.000 claims 1
- 102220577884 Leucine-rich repeat serine/threonine-protein kinase 2_Y1699C_mutation Human genes 0.000 claims 1
- 102220577894 Leucine-rich repeat serine/threonine-protein kinase 2_Y2189C_mutation Human genes 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 114
- 229910052739 hydrogen Inorganic materials 0.000 description 102
- 238000000034 method Methods 0.000 description 87
- 239000011541 reaction mixture Substances 0.000 description 68
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 66
- 239000002904 solvent Substances 0.000 description 59
- 239000007787 solid Substances 0.000 description 51
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 50
- 238000006243 chemical reaction Methods 0.000 description 49
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 38
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 33
- 239000000203 mixture Substances 0.000 description 31
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 30
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 30
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 28
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 28
- NROKBHXJSPEDAR-UHFFFAOYSA-M potassium fluoride Chemical compound [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 description 28
- CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 28
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 27
- 238000006880 cross-coupling reaction Methods 0.000 description 26
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 26
- 238000005160 1H NMR spectroscopy Methods 0.000 description 24
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 24
- 238000010438 heat treatment Methods 0.000 description 24
- 239000003054 catalyst Substances 0.000 description 22
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 20
- 108091000080 Phosphotransferase Proteins 0.000 description 19
- 102000020233 phosphotransferase Human genes 0.000 description 19
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 18
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 18
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 18
- 239000000243 solution Substances 0.000 description 18
- 239000000463 material Substances 0.000 description 17
- 102200092160 rs34637584 Human genes 0.000 description 17
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 16
- MXQOYLRVSVOCQT-UHFFFAOYSA-N palladium;tritert-butylphosphane Chemical compound [Pd].CC(C)(C)P(C(C)(C)C)C(C)(C)C.CC(C)(C)P(C(C)(C)C)C(C)(C)C MXQOYLRVSVOCQT-UHFFFAOYSA-N 0.000 description 16
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 16
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 15
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
- 239000012267 brine Substances 0.000 description 15
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 15
- 235000019341 magnesium sulphate Nutrition 0.000 description 15
- 239000012074 organic phase Substances 0.000 description 15
- 230000002829 reductive effect Effects 0.000 description 15
- 230000000694 effects Effects 0.000 description 14
- 239000011698 potassium fluoride Substances 0.000 description 14
- 235000003270 potassium fluoride Nutrition 0.000 description 14
- 230000008569 process Effects 0.000 description 14
- 238000010828 elution Methods 0.000 description 13
- 239000000284 extract Substances 0.000 description 13
- 229910000027 potassium carbonate Inorganic materials 0.000 description 13
- 239000000741 silica gel Substances 0.000 description 13
- 229910002027 silica gel Inorganic materials 0.000 description 13
- 229910052723 transition metal Inorganic materials 0.000 description 13
- 150000003624 transition metals Chemical class 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 12
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 12
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 12
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 12
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 11
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 11
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 11
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 10
- 238000006069 Suzuki reaction reaction Methods 0.000 description 10
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 10
- 235000019253 formic acid Nutrition 0.000 description 10
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 10
- 230000026731 phosphorylation Effects 0.000 description 10
- 238000006366 phosphorylation reaction Methods 0.000 description 10
- 239000007983 Tris buffer Substances 0.000 description 9
- 239000002253 acid Substances 0.000 description 9
- 238000002877 time resolved fluorescence resonance energy transfer Methods 0.000 description 9
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 8
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 8
- 239000010410 layer Substances 0.000 description 8
- HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 8
- KACVWNPHKPVGLF-UHFFFAOYSA-N 1-(benzenesulfonyl)-4-chloropyrrolo[2,3-b]pyridine-3-carbonitrile Chemical compound C1=C(C#N)C=2C(Cl)=CC=NC=2N1S(=O)(=O)C1=CC=CC=C1 KACVWNPHKPVGLF-UHFFFAOYSA-N 0.000 description 7
- UVZULFCBDHDUBG-UHFFFAOYSA-N 4,6-dichloro-1H-pyrrolo[2,3-b]pyridine-3-carbonitrile Chemical compound Clc1cc(Cl)c2c(c[nH]c2n1)C#N UVZULFCBDHDUBG-UHFFFAOYSA-N 0.000 description 7
- XQAJHQBDIDWDGZ-UHFFFAOYSA-N 4-chloro-1h-pyrrolo[2,3-b]pyridine-3-carbonitrile Chemical compound ClC1=CC=NC2=C1C(C#N)=CN2 XQAJHQBDIDWDGZ-UHFFFAOYSA-N 0.000 description 7
- 238000005481 NMR spectroscopy Methods 0.000 description 7
- 150000001412 amines Chemical class 0.000 description 7
- 238000001816 cooling Methods 0.000 description 7
- 238000005859 coupling reaction Methods 0.000 description 7
- 239000003085 diluting agent Substances 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 239000008194 pharmaceutical composition Substances 0.000 description 7
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 description 7
- 125000006239 protecting group Chemical group 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- YSZSLPRWNYBWRS-LSFNHRITSA-N (2S,9S,12R)-2-cyclohexyl-12-[2-(3,4-dimethoxyphenyl)ethyl]-24,27-dimethoxy-11,18,22-trioxa-4-azatetracyclo[21.2.2.113,17.04,9]octacosa-1(25),13(28),14,16,23,26-hexaene-3,10-dione Chemical compound COC1=C(C=C(C=C1)CC[C@@H]2C3=CC(=CC=C3)OCCCOC4=C(C=C(C=C4OC)[C@@H](C(=O)N5CCCC[C@H]5C(=O)O2)C6CCCCC6)OC)OC YSZSLPRWNYBWRS-LSFNHRITSA-N 0.000 description 6
- WMKGGPCROCCUDY-UHFFFAOYSA-N 1,5-diphenylpenta-1,4-dien-3-one Chemical compound C=1C=CC=CC=1C=CC(=O)C=CC1=CC=CC=C1 WMKGGPCROCCUDY-UHFFFAOYSA-N 0.000 description 6
- 125000003821 2-(trimethylsilyl)ethoxymethyl group Chemical group [H]C([H])([H])[Si](C([H])([H])[H])(C([H])([H])[H])C([H])([H])C(OC([H])([H])[*])([H])[H] 0.000 description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 6
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 6
- 229910052771 Terbium Inorganic materials 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- 210000004556 brain Anatomy 0.000 description 6
- FDLDWKIEWAWOSL-UHFFFAOYSA-N ethyl acetate;2-methylpentane Chemical compound CCCC(C)C.CCOC(C)=O FDLDWKIEWAWOSL-UHFFFAOYSA-N 0.000 description 6
- 239000012071 phase Substances 0.000 description 6
- 102200092155 rs35870237 Human genes 0.000 description 6
- 238000010898 silica gel chromatography Methods 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- GZCRRIHWUXGPOV-UHFFFAOYSA-N terbium atom Chemical compound [Tb] GZCRRIHWUXGPOV-UHFFFAOYSA-N 0.000 description 6
- 239000003981 vehicle Substances 0.000 description 6
- GZPHSAQLYPIAIN-UHFFFAOYSA-N 3-pyridinecarbonitrile Chemical compound N#CC1=CC=CN=C1 GZPHSAQLYPIAIN-UHFFFAOYSA-N 0.000 description 5
- ZIPRNOCBJBERDQ-UHFFFAOYSA-N 4-chloro-6-[(1-methylpyrazol-3-yl)amino]-1H-pyrrolo[2,3-b]pyridine-3-carbonitrile Chemical compound Cn1ccc(Nc2cc(Cl)c3c(c[nH]c3n2)C#N)n1 ZIPRNOCBJBERDQ-UHFFFAOYSA-N 0.000 description 5
- PWYOTERVNDEWIQ-UHFFFAOYSA-N 6-chloro-4-iodo-1-(2-trimethylsilylethoxymethyl)pyrrolo[2,3-b]pyridine-3-carbonitrile Chemical compound C[Si](C)(C)CCOCn1cc(C#N)c2c(I)cc(Cl)nc12 PWYOTERVNDEWIQ-UHFFFAOYSA-N 0.000 description 5
- 239000004215 Carbon black (E152) Substances 0.000 description 5
- LELOWRISYMNNSU-UHFFFAOYSA-N Hydrocyanic acid Natural products N#C LELOWRISYMNNSU-UHFFFAOYSA-N 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 5
- 229940024606 amino acid Drugs 0.000 description 5
- 230000008878 coupling Effects 0.000 description 5
- 238000010168 coupling process Methods 0.000 description 5
- 125000004093 cyano group Chemical group *C#N 0.000 description 5
- 125000004122 cyclic group Chemical group 0.000 description 5
- 229960003638 dopamine Drugs 0.000 description 5
- 210000005064 dopaminergic neuron Anatomy 0.000 description 5
- 239000003937 drug carrier Substances 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 5
- 238000003818 flash chromatography Methods 0.000 description 5
- 125000000623 heterocyclic group Chemical group 0.000 description 5
- 229930195733 hydrocarbon Natural products 0.000 description 5
- 150000002430 hydrocarbons Chemical class 0.000 description 5
- 239000001257 hydrogen Substances 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 210000004558 lewy body Anatomy 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- BJQCPCFFYBKRLM-UHFFFAOYSA-N (3-methylphenyl)boronic acid Chemical compound CC1=CC=CC(B(O)O)=C1 BJQCPCFFYBKRLM-UHFFFAOYSA-N 0.000 description 4
- AQBOYYZSUOZULE-UHFFFAOYSA-N 6-chloro-4-iodo-1H-pyrrolo[2,3-b]pyridine-3-carbonitrile Chemical compound Clc1cc(I)c2c(c[nH]c2n1)C#N AQBOYYZSUOZULE-UHFFFAOYSA-N 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 4
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 4
- AMNWFWVFDOJUHD-UHFFFAOYSA-N [O-][n+]1ccc(Cl)c2c(c[nH]c12)C#N Chemical compound [O-][n+]1ccc(Cl)c2c(c[nH]c12)C#N AMNWFWVFDOJUHD-UHFFFAOYSA-N 0.000 description 4
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 4
- 239000012346 acetyl chloride Substances 0.000 description 4
- 125000000217 alkyl group Chemical group 0.000 description 4
- 230000035578 autophosphorylation Effects 0.000 description 4
- CSKNSYBAZOQPLR-UHFFFAOYSA-N benzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC=C1 CSKNSYBAZOQPLR-UHFFFAOYSA-N 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 102200092223 rs33939927 Human genes 0.000 description 4
- 102200092216 rs34995376 Human genes 0.000 description 4
- 102200092167 rs35801418 Human genes 0.000 description 4
- 235000009518 sodium iodide Nutrition 0.000 description 4
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- SSVPHQYUDZPVQX-UHFFFAOYSA-N (4-formyl-3-methylphenyl)boronic acid Chemical compound CC1=CC(B(O)O)=CC=C1C=O SSVPHQYUDZPVQX-UHFFFAOYSA-N 0.000 description 3
- UKSKUKSHYGZUTH-UHFFFAOYSA-N 1-(benzenesulfonyl)-4,6-dichloropyrrolo[2,3-b]pyridine-3-carbonitrile Chemical compound Clc1cc(Cl)c2c(cn(c2n1)S(=O)(=O)c1ccccc1)C#N UKSKUKSHYGZUTH-UHFFFAOYSA-N 0.000 description 3
- PYDGENDNSZYWIE-UHFFFAOYSA-N 1-(benzenesulfonyl)-4-(4-formyl-3-methylphenyl)pyrrolo[2,3-b]pyridine-3-carbonitrile Chemical compound Cc1cc(ccc1C=O)-c1ccnc2n(cc(C#N)c12)S(=O)(=O)c1ccccc1 PYDGENDNSZYWIE-UHFFFAOYSA-N 0.000 description 3
- YCJLJJMUNYRPFA-UHFFFAOYSA-N 1-(benzenesulfonyl)-4-[1-(morpholin-4-ylmethyl)pyrrol-3-yl]pyrrolo[2,3-b]pyridine-3-carbonitrile Chemical compound O=S(=O)(c1ccccc1)n1cc(C#N)c2c(ccnc12)-c1ccn(CN2CCOCC2)c1 YCJLJJMUNYRPFA-UHFFFAOYSA-N 0.000 description 3
- BPXKZEMBEZGUAH-UHFFFAOYSA-N 2-(chloromethoxy)ethyl-trimethylsilane Chemical compound C[Si](C)(C)CCOCCl BPXKZEMBEZGUAH-UHFFFAOYSA-N 0.000 description 3
- WNISYBBPBUGRTG-UHFFFAOYSA-N 4-(4-formyl-3-methylphenyl)-6-[(1-methylpyrazol-3-yl)amino]-1H-pyrrolo[2,3-b]pyridine-3-carbonitrile Chemical compound Cc1cc(ccc1C=O)-c1cc(Nc2ccn(C)n2)nc2[nH]cc(C#N)c12 WNISYBBPBUGRTG-UHFFFAOYSA-N 0.000 description 3
- PSCIVEPEARWYTD-UHFFFAOYSA-N 4-[1-(morpholin-4-ylmethyl)pyrrol-3-yl]-1h-pyrrolo[2,3-b]pyridine-3-carbonitrile Chemical compound C=12C(C#N)=CNC2=NC=CC=1C(=C1)C=CN1CN1CCOCC1 PSCIVEPEARWYTD-UHFFFAOYSA-N 0.000 description 3
- QBVSOZPKIAVIHW-UHFFFAOYSA-N 4-chloro-6-(pyridin-2-ylamino)-1H-pyrrolo[2,3-b]pyridine-3-carbonitrile Chemical compound Clc1cc(Nc2ccccn2)nc2[nH]cc(C#N)c12 QBVSOZPKIAVIHW-UHFFFAOYSA-N 0.000 description 3
- NJNUNSNMSXJULV-UHFFFAOYSA-N 6-(benzylamino)-4-chloro-1H-pyrrolo[2,3-b]pyridine-3-carbonitrile Chemical compound Clc1cc(NCc2ccccc2)nc2[nH]cc(C#N)c12 NJNUNSNMSXJULV-UHFFFAOYSA-N 0.000 description 3
- WBVLZQGMDLMNDD-UHFFFAOYSA-N 6-amino-4-chloro-1H-pyrrolo[2,3-b]pyridine-3-carbonitrile Chemical compound Nc1cc(Cl)c2c(c[nH]c2n1)C#N WBVLZQGMDLMNDD-UHFFFAOYSA-N 0.000 description 3
- JKSJAQPNHHRVMQ-UHFFFAOYSA-N 6-chloro-4-(4-methylpyridin-2-yl)-1-(2-trimethylsilylethoxymethyl)pyrrolo[2,3-b]pyridine-3-carbonitrile Chemical compound Cc1ccnc(c1)-c1cc(Cl)nc2n(COCC[Si](C)(C)C)cc(C#N)c12 JKSJAQPNHHRVMQ-UHFFFAOYSA-N 0.000 description 3
- TVBDOSHULAJFMT-UHFFFAOYSA-N 6-chloro-4-(5-methylpyridin-3-yl)-1-(2-trimethylsilylethoxymethyl)pyrrolo[2,3-b]pyridine-3-carbonitrile Chemical compound Cc1cncc(c1)-c1cc(Cl)nc2n(COCC[Si](C)(C)C)cc(C#N)c12 TVBDOSHULAJFMT-UHFFFAOYSA-N 0.000 description 3
- BCUBMDJGORFPLE-UHFFFAOYSA-N 6-chloro-4-(5-methylpyridin-3-yl)-1H-pyrrolo[2,3-b]pyridine-3-carbonitrile Chemical compound Cc1cncc(c1)-c1cc(Cl)nc2[nH]cc(C#N)c12 BCUBMDJGORFPLE-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- HUBVAOMVEMGRFA-UHFFFAOYSA-N [1-tri(propan-2-yl)silylpyrrol-3-yl]boronic acid Chemical compound CC(C)[Si](C(C)C)(C(C)C)N1C=CC(B(O)O)=C1 HUBVAOMVEMGRFA-UHFFFAOYSA-N 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 125000000440 benzylamino group Chemical group [H]N(*)C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 239000003638 chemical reducing agent Substances 0.000 description 3
- LZWLLMFYVGUUAL-UHFFFAOYSA-L ditert-butyl(cyclopenta-1,3-dien-1-yl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.CC(C)(C)P(C(C)(C)C)C1=CC=C[CH-]1.CC(C)(C)P(C(C)(C)C)C1=CC=C[CH-]1 LZWLLMFYVGUUAL-UHFFFAOYSA-L 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 229940098779 methanesulfonic acid Drugs 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 239000003208 petroleum Substances 0.000 description 3
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 3
- 238000006268 reductive amination reaction Methods 0.000 description 3
- 102200092166 rs11564148 Human genes 0.000 description 3
- 102200092222 rs33939927 Human genes 0.000 description 3
- 102200092172 rs33949390 Human genes 0.000 description 3
- 102200092170 rs35303786 Human genes 0.000 description 3
- 102200092221 rs7133914 Human genes 0.000 description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 description 3
- 235000011152 sodium sulphate Nutrition 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 2
- GZJVUJXNJCCGEC-UHFFFAOYSA-N 1,4-dimethylpyrazol-3-amine Chemical compound CC1=CN(C)N=C1N GZJVUJXNJCCGEC-UHFFFAOYSA-N 0.000 description 2
- RNHDAKUGFHSZEV-UHFFFAOYSA-N 1,4-dioxane;hydrate Chemical compound O.C1COCCO1 RNHDAKUGFHSZEV-UHFFFAOYSA-N 0.000 description 2
- SHDQYUNCORWTSH-UHFFFAOYSA-N 1-(3-methylphenyl)pyrrolo[2,3-b]pyridine-3-carbonitrile Chemical compound CC=1C=C(C=CC=1)N1C=C(C=2C1=NC=CC=2)C#N SHDQYUNCORWTSH-UHFFFAOYSA-N 0.000 description 2
- IYLOEUBCKLJSAZ-UHFFFAOYSA-N 1-(benzenesulfonyl)-4-(3-chloro-4-formylphenyl)pyrrolo[2,3-b]pyridine-3-carbonitrile Chemical compound C(=O)C1=CC=C(C=C1Cl)C1=C2C(=CN(C2=NC=C1)S(=O)(=O)C1=CC=CC=C1)C#N IYLOEUBCKLJSAZ-UHFFFAOYSA-N 0.000 description 2
- FTXRCQLHUANHAU-UHFFFAOYSA-N 1-(benzenesulfonyl)-4-[3-methyl-4-(morpholin-4-ylmethyl)phenyl]pyrrolo[2,3-b]pyridine-3-carbonitrile Chemical compound CC1=CC(=CC=C1CN1CCOCC1)C1=C2C(=CN(C2=NC=C1)S(=O)(=O)C1=CC=CC=C1)C#N FTXRCQLHUANHAU-UHFFFAOYSA-N 0.000 description 2
- TUVWIIDXCDHWDH-UHFFFAOYSA-N 1-methyl-4-(trifluoromethyl)pyrazol-3-amine Chemical compound Cn1cc(c(N)n1)C(F)(F)F TUVWIIDXCDHWDH-UHFFFAOYSA-N 0.000 description 2
- MOGQNVSKBCVIPW-UHFFFAOYSA-N 1-methylpyrazol-3-amine Chemical compound CN1C=CC(N)=N1 MOGQNVSKBCVIPW-UHFFFAOYSA-N 0.000 description 2
- AFABGHUZZDYHJO-UHFFFAOYSA-N 2-Methylpentane Chemical compound CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 2
- ICSNLGPSRYBMBD-UHFFFAOYSA-N 2-aminopyridine Chemical compound NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 description 2
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 2
- 125000001397 3-pyrrolyl group Chemical group [H]N1C([H])=C([*])C([H])=C1[H] 0.000 description 2
- CVODQVUUQPDPGH-UHFFFAOYSA-N 4-(3-ethenyl-4-formylphenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonitrile Chemical compound C(=O)C1=CC=C(C=C1C=C)C1=C2C(NC=C2C#N)=NC=C1 CVODQVUUQPDPGH-UHFFFAOYSA-N 0.000 description 2
- HNKYZXHDSZUVRW-UHFFFAOYSA-N 4-(5-methylpyridin-3-yl)-6-[[1-methyl-4-(trifluoromethyl)pyrazol-3-yl]amino]-1-(2-trimethylsilylethoxymethyl)pyrrolo[2,3-b]pyridine-3-carbonitrile Chemical compound Cc1cncc(c1)-c1cc(Nc2nn(C)cc2C(F)(F)F)nc2n(COCC[Si](C)(C)C)cc(C#N)c12 HNKYZXHDSZUVRW-UHFFFAOYSA-N 0.000 description 2
- CIMGYBFULZABLN-UHFFFAOYSA-N 4-chloro-6-[(1-methylpyrazol-4-yl)amino]-1H-pyrrolo[2,3-b]pyridine-3-carbonitrile Chemical compound Cn1cc(Nc2cc(Cl)c3c(c[nH]c3n2)C#N)cn1 CIMGYBFULZABLN-UHFFFAOYSA-N 0.000 description 2
- HKHYKFBCTYTOJJ-UHFFFAOYSA-N 6-chloro-4-(2-methylpyridin-4-yl)-1-(2-trimethylsilylethoxymethyl)pyrrolo[2,3-b]pyridine-3-carbonitrile Chemical compound Cc1cc(ccn1)-c1cc(Cl)nc2n(COCC[Si](C)(C)C)cc(C#N)c12 HKHYKFBCTYTOJJ-UHFFFAOYSA-N 0.000 description 2
- LGFLEBQAUAHABT-UHFFFAOYSA-N 6-chloro-4-(6-methylpyridin-2-yl)-1-(2-trimethylsilylethoxymethyl)pyrrolo[2,3-b]pyridine-3-carbonitrile Chemical compound Cc1cccc(n1)-c1cc(Cl)nc2n(COCC[Si](C)(C)C)cc(C#N)c12 LGFLEBQAUAHABT-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 206010009900 Colitis ulcerative Diseases 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 206010024229 Leprosy Diseases 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 208000009829 Lewy Body Disease Diseases 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 206010033701 Papillary thyroid cancer Diseases 0.000 description 2
- 235000019483 Peanut oil Nutrition 0.000 description 2
- 206010038389 Renal cancer Diseases 0.000 description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 description 2
- 230000001594 aberrant effect Effects 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- GBRBMTNGQBKBQE-UHFFFAOYSA-L copper;diiodide Chemical compound I[Cu]I GBRBMTNGQBKBQE-UHFFFAOYSA-L 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- WDUDHEOUGWAKFD-UHFFFAOYSA-N ditert-butyl(cyclopenta-2,4-dien-1-yl)phosphane;iron(2+) Chemical compound [Fe+2].CC(C)(C)P(C(C)(C)C)C1=CC=C[CH-]1.CC(C)(C)P(C(C)(C)C)C1=CC=C[CH-]1 WDUDHEOUGWAKFD-UHFFFAOYSA-N 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 238000007429 general method Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 201000010982 kidney cancer Diseases 0.000 description 2
- 229940043355 kinase inhibitor Drugs 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 2
- 230000004770 neurodegeneration Effects 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- MUJIDPITZJWBSW-UHFFFAOYSA-N palladium(2+) Chemical compound [Pd+2] MUJIDPITZJWBSW-UHFFFAOYSA-N 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000000312 peanut oil Substances 0.000 description 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 102000054765 polymorphisms of proteins Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- YLHJACXHRQQNQR-UHFFFAOYSA-N pyridine;2,4,6-tris(ethenyl)-1,3,5,2,4,6-trioxatriborinane Chemical compound C1=CC=NC=C1.C=CB1OB(C=C)OB(C=C)O1 YLHJACXHRQQNQR-UHFFFAOYSA-N 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 102200092154 rs34778348 Human genes 0.000 description 2
- 102220010596 rs35658131 Human genes 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- SHMPGQWVDZTZBX-UHFFFAOYSA-N tributyl-(4-methylpyridin-2-yl)stannane Chemical compound CCCC[Sn](CCCC)(CCCC)C1=CC(C)=CC=N1 SHMPGQWVDZTZBX-UHFFFAOYSA-N 0.000 description 2
- BWHDROKFUHTORW-UHFFFAOYSA-N tritert-butylphosphane Chemical compound CC(C)(C)P(C(C)(C)C)C(C)(C)C BWHDROKFUHTORW-UHFFFAOYSA-N 0.000 description 2
- 238000000825 ultraviolet detection Methods 0.000 description 2
- UFYBTLOLWSABAU-UHFFFAOYSA-N (2-methylpyridin-4-yl)boronic acid Chemical compound CC1=CC(B(O)O)=CC=N1 UFYBTLOLWSABAU-UHFFFAOYSA-N 0.000 description 1
- KDIYVLXLPNHJRZ-UHFFFAOYSA-N (3-chloro-4-formylphenyl)boronic acid Chemical compound OB(O)C1=CC=C(C=O)C(Cl)=C1 KDIYVLXLPNHJRZ-UHFFFAOYSA-N 0.000 description 1
- JIMVRUCDZGFJRE-UHFFFAOYSA-N (3-ethylphenyl)boronic acid Chemical compound CCC1=CC=CC(B(O)O)=C1 JIMVRUCDZGFJRE-UHFFFAOYSA-N 0.000 description 1
- NLLGFYPSWCMUIV-UHFFFAOYSA-N (3-methoxyphenyl)boronic acid Chemical compound COC1=CC=CC(B(O)O)=C1 NLLGFYPSWCMUIV-UHFFFAOYSA-N 0.000 description 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- YXRDJFSITLAECR-UHFFFAOYSA-N 1-(benzenesulfonyl)-4-(1H-pyrrol-3-yl)pyrrolo[2,3-b]pyridine-3-carbonitrile Chemical compound C1(=CC=CC=C1)S(=O)(=O)N1C=C(C=2C1=NC=CC2C2=CNC=C2)C#N YXRDJFSITLAECR-UHFFFAOYSA-N 0.000 description 1
- LBGSWBJURUFGLR-UHFFFAOYSA-N 1-methylpyrazol-4-amine Chemical compound CN1C=C(N)C=N1 LBGSWBJURUFGLR-UHFFFAOYSA-N 0.000 description 1
- MUCWDACENIACBH-UHFFFAOYSA-N 1h-pyrrolo[2,3-b]pyridine-3-carbonitrile Chemical compound C1=CC=C2C(C#N)=CNC2=N1 MUCWDACENIACBH-UHFFFAOYSA-N 0.000 description 1
- IEQAICDLOKRSRL-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO IEQAICDLOKRSRL-UHFFFAOYSA-N 0.000 description 1
- NRGGMCIBEHEAIL-UHFFFAOYSA-N 2-ethylpyridine Chemical compound CCC1=CC=CC=N1 NRGGMCIBEHEAIL-UHFFFAOYSA-N 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- OEVTWWHWRQEFQI-UHFFFAOYSA-N 4-[3-ethenyl-4-(morpholin-4-ylmethyl)phenyl]-1H-pyrrolo[2,3-b]pyridine-3-carbonitrile Chemical compound C=CC1=CC(=CC=C1CN1CCOCC1)C1=C2C(NC=C2C#N)=NC=C1 OEVTWWHWRQEFQI-UHFFFAOYSA-N 0.000 description 1
- MGZVMXARJNUNDE-UHFFFAOYSA-N 4-[4-[(dimethylamino)methyl]-3-methylphenyl]-1h-pyrrolo[2,3-b]pyridine-3-carbonitrile Chemical compound C1=C(C)C(CN(C)C)=CC=C1C1=CC=NC2=C1C(C#N)=CN2 MGZVMXARJNUNDE-UHFFFAOYSA-N 0.000 description 1
- LHQLULJEAHPAHY-UHFFFAOYSA-N 4-chloro-1-methylpyrazol-3-amine Chemical compound CN1C=C(Cl)C(N)=N1 LHQLULJEAHPAHY-UHFFFAOYSA-N 0.000 description 1
- IDXHKLGFSAKIAC-UHFFFAOYSA-N 6-[(1,4-dimethylpyrazol-3-yl)amino]-4-(2-methylpyridin-4-yl)-1-(2-trimethylsilylethoxymethyl)pyrrolo[2,3-b]pyridine-3-carbonitrile Chemical compound Cc1cn(C)nc1Nc1cc(-c2ccnc(C)c2)c2c(cn(COCC[Si](C)(C)C)c2n1)C#N IDXHKLGFSAKIAC-UHFFFAOYSA-N 0.000 description 1
- FEJJEFINKVJIRN-UHFFFAOYSA-N 6-[(1,4-dimethylpyrazol-3-yl)amino]-4-(6-methylpyridin-2-yl)-1-(2-trimethylsilylethoxymethyl)pyrrolo[2,3-b]pyridine-3-carbonitrile Chemical compound Cc1cn(C)nc1Nc1cc(-c2cccc(C)n2)c2c(cn(COCC[Si](C)(C)C)c2n1)C#N FEJJEFINKVJIRN-UHFFFAOYSA-N 0.000 description 1
- HDMNUACGSWFOHC-UHFFFAOYSA-N 6-[(1-methylpyrazol-3-yl)amino]-4-(5-methylpyridin-3-yl)-1-(2-trimethylsilylethoxymethyl)pyrrolo[2,3-b]pyridine-3-carbonitrile Chemical compound Cc1cncc(c1)-c1cc(Nc2ccn(C)n2)nc2n(COCC[Si](C)(C)C)cc(C#N)c12 HDMNUACGSWFOHC-UHFFFAOYSA-N 0.000 description 1
- GECWBBGPYTZGNI-UHFFFAOYSA-N 6-[(4-chloro-1-methylpyrazol-3-yl)amino]-4-(4-methylpyridin-2-yl)-1-(2-trimethylsilylethoxymethyl)pyrrolo[2,3-b]pyridine-3-carbonitrile Chemical compound Cc1ccnc(c1)-c1cc(Nc2nn(C)cc2Cl)nc2n(COCC[Si](C)(C)C)cc(C#N)c12 GECWBBGPYTZGNI-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 1
- 102000003823 Aromatic-L-amino-acid decarboxylases Human genes 0.000 description 1
- 108090000121 Aromatic-L-amino-acid decarboxylases Proteins 0.000 description 1
- 206010006100 Bradykinesia Diseases 0.000 description 1
- 101100037762 Caenorhabditis elegans rnh-2 gene Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 241000400611 Eucalyptus deanei Species 0.000 description 1
- 244000166102 Eucalyptus leucoxylon Species 0.000 description 1
- 235000004694 Eucalyptus leucoxylon Nutrition 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 238000007341 Heck reaction Methods 0.000 description 1
- 101000941879 Homo sapiens Leucine-rich repeat serine/threonine-protein kinase 2 Proteins 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010052904 Musculoskeletal stiffness Diseases 0.000 description 1
- 239000007832 Na2SO4 Substances 0.000 description 1
- 208000027089 Parkinsonian disease Diseases 0.000 description 1
- 206010034010 Parkinsonism Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 238000006619 Stille reaction Methods 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 108090000848 Ubiquitin Proteins 0.000 description 1
- 102000044159 Ubiquitin Human genes 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- KMWLUGSVWULTHR-UHFFFAOYSA-N [4-(aminomethyl)phenyl]boronic acid Chemical compound NCC1=CC=C(B(O)O)C=C1 KMWLUGSVWULTHR-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 150000004982 aromatic amines Chemical class 0.000 description 1
- 150000001543 aryl boronic acids Chemical class 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229940090047 auto-injector Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 150000001642 boronic acid derivatives Chemical class 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- DLIJPAHLBJIQHE-UHFFFAOYSA-N butylphosphane Chemical compound CCCCP DLIJPAHLBJIQHE-UHFFFAOYSA-N 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 229960004205 carbidopa Drugs 0.000 description 1
- TZFNLOMSOLWIDK-JTQLQIEISA-N carbidopa (anhydrous) Chemical compound NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 TZFNLOMSOLWIDK-JTQLQIEISA-N 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- MHUWZNTUIIFHAS-CLFAGFIQSA-N dioleoyl phosphatidic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(O)=O)OC(=O)CCCCCCC\C=C/CCCCCCCC MHUWZNTUIIFHAS-CLFAGFIQSA-N 0.000 description 1
- WJJMNDUMQPNECX-UHFFFAOYSA-N dipicolinic acid Chemical compound OC(=O)C1=CC=CC(C(O)=O)=N1 WJJMNDUMQPNECX-UHFFFAOYSA-N 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 229940052760 dopamine agonists Drugs 0.000 description 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 1
- 229940052764 dopaminergic anti-parkinson drug mao b inhibitors Drugs 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 125000003709 fluoroalkyl group Chemical group 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 1
- 102000056111 human LRRK2 Human genes 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 238000001871 ion mobility spectroscopy Methods 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 150000002519 isoleucine derivatives Chemical class 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000003674 kinase activity assay Methods 0.000 description 1
- 229960004502 levodopa Drugs 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 238000010197 meta-analysis Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 125000006574 non-aromatic ring group Chemical group 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 230000003950 pathogenic mechanism Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 229960005235 piperonyl butoxide Drugs 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- 150000003870 salicylic acids Chemical class 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- USKQYZHWJZDNCM-UHFFFAOYSA-N tributyl-(6-methylpyridin-2-yl)stannane Chemical compound CCCC[Sn](CCCC)(CCCC)C1=CC=CC(C)=N1 USKQYZHWJZDNCM-UHFFFAOYSA-N 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DK201300231 | 2013-04-18 | ||
| DKPA201300231 | 2013-04-18 | ||
| PCT/EP2014/057482 WO2014170248A1 (en) | 2013-04-18 | 2014-04-14 | Arylpyrrolopyridine derived compounds as lrrk2 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2642204T3 true ES2642204T3 (es) | 2017-11-15 |
Family
ID=59093654
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES14720062.0T Active ES2642204T3 (es) | 2013-04-18 | 2014-04-14 | Compuestos derivados de arilpirrolopiridina como inhibidores de LRRK2 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US9499542B2 (enExample) |
| EP (1) | EP2986608B1 (enExample) |
| JP (1) | JP6461097B2 (enExample) |
| CN (1) | CN105263930B (enExample) |
| AR (1) | AR095885A1 (enExample) |
| ES (1) | ES2642204T3 (enExample) |
| TW (1) | TW201533043A (enExample) |
| WO (1) | WO2014170248A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201533043A (zh) | 2013-04-18 | 2015-09-01 | Lundbeck & Co As H | 作爲ｌｒｒｋ２抑制劑的芳基吡咯并吡啶衍生化合物 |
| US11214565B2 (en) | 2015-11-20 | 2022-01-04 | Denali Therapeutics Inc. | Compound, compositions, and methods |
| CN108934162A (zh) | 2015-12-16 | 2018-12-04 | 南方研究所 | 吡咯并嘧啶化合物、作为激酶lrrk2抑制剂的用途及其制备方法 |
| US11028080B2 (en) | 2016-03-11 | 2021-06-08 | Denali Therapeutics Inc. | Substituted pyrimidines as LRKK2 inhibitors |
| PT3472153T (pt) | 2016-06-16 | 2021-12-31 | Denali Therapeutics Inc | Pirimidin-2-ilamino-1h-pirazóis como inibidores de lrrk2 para uso no tratamento de distúrbios neurodegenerativos |
| US10034861B2 (en) | 2016-07-04 | 2018-07-31 | H. Lundbeck A/S | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors |
| JOP20190126A1 (ar) * | 2016-12-22 | 2019-05-28 | H Lundbeck As | بيرازولو [3، 4-b] بيريدينات وإيميدازو [1، 5-b] بيريدازينات على هيئة مثبطات PDE1 |
| SG11201908234WA (en) | 2017-02-24 | 2019-10-30 | Daegu Gyeongbuk Medical Innovation Found | Pharmaceutical composition comprising compound capable of penetrating blood-brain barrier as effective ingredient for preventing or treating brain cancer |
| FI3604304T3 (fi) * | 2017-03-23 | 2022-12-15 | Pyrrolopyridiinijohdannaisyhdiste, menetelmä sen valmistamiseksi ja sitä vaikuttavana ainesosana sisältävä farmaseuttinen koostumus proteiinikinaasiin liittyvien tautien ehkäisemiseksi tai hoitamiseksi | |
| KR20190043437A (ko) * | 2017-10-18 | 2019-04-26 | 씨제이헬스케어 주식회사 | 단백질 키나제 억제제로서의 헤테로고리 화합물 |
| JP7230053B2 (ja) * | 2017-12-05 | 2023-02-28 | オスコテック インコーポレイテッド | Ｌｒｒｋ２阻害剤としてのピロロ（ピラゾロ）ピリミジン誘導体 |
| AR113926A1 (es) | 2017-12-14 | 2020-07-01 | H Lundbeck As | Derivados de 1h-pirazolo[4,3-b]piridinas |
| RU2020118913A (ru) | 2017-12-14 | 2022-01-14 | Х. Лундбекк А/С (H. Lundbeck A/S) | Виды комбинированного лечения, предусматривающего введение 1h-пиразолo[4,3-b]пиридинов |
| US11535611B2 (en) | 2017-12-20 | 2022-12-27 | H. Lundbeck A/S | Pyrazolo[3,4-B]pyridines and imidazo[1,5-B]pyridazines as PDE1 inhibitors |
| WO2020023393A1 (en) * | 2018-07-23 | 2020-01-30 | Bioblocks, Inc. | Kinase antagonists and methods for making and using them |
| KR101990739B1 (ko) * | 2018-07-24 | 2019-06-19 | 재단법인 대구경북첨단의료산업진흥재단 | 혈액 뇌관문을 통과할 수 있는 화합물을 유효성분으로 함유하는 뇌암의 예방 또는 치료용 약학적 조성물 |
| KR101992059B1 (ko) * | 2018-08-23 | 2019-06-21 | 재단법인 대구경북첨단의료산업진흥재단 | 혈액 뇌관문을 통과할 수 있는 화합물을 유효성분으로 함유하는 뇌암의 예방 또는 치료용 약학적 조성물 |
| KR102195348B1 (ko) | 2018-11-15 | 2020-12-24 | 에이치케이이노엔 주식회사 | 단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물 |
| EP3915985A4 (en) | 2019-01-18 | 2022-09-28 | Voronoi Co., Ltd. | PYRROLOPYRIDE DERIVATIVE AND USE THEREOF FOR THE PREVENTION AND TREATMENT OF PROTEIN KINASE RELATED DISEASES |
| KR102133595B1 (ko) * | 2019-05-31 | 2020-07-13 | 에이치케이이노엔 주식회사 | 단백질 키나제 억제제로서의 헤테로고리 화합물 |
| AU2021371697B2 (en) * | 2020-10-29 | 2024-10-24 | Suzhou Yabao Pharmaceutical R&D Co., Ltd. | Substituted diarylamine compound, pharmaceutical composition thereof, preparation method therefor, and use thereof |
| KR20220081631A (ko) | 2020-12-09 | 2022-06-16 | 보로노이 주식회사 | 염증성 질환의 예방 및/또는 치료를 위한 피롤로-피리딘 유도체 화합물의 신규 용도 |
| CN112852954A (zh) * | 2021-03-16 | 2021-05-28 | 江苏贝格尔生物医药有限公司 | 一种检测lrrk2基因1628多态性的引物和探针及试剂盒 |
| WO2023076404A1 (en) | 2021-10-27 | 2023-05-04 | Aria Pharmaceuticals, Inc. | Methods for treating systemic lupus erythematosus |
| US20250361230A1 (en) * | 2022-06-06 | 2025-11-27 | The USA, as Represented by the Secretary, Dept. of Heath and Human Services | LATS Inhibitors and Uses Thereof |
| CN119707961B (zh) * | 2024-12-02 | 2025-10-24 | 重庆飞因科生物科技有限公司 | 吡啶并吡咯类氨基酸衍生物及其在制备富亮氨酸重复激酶2抑制剂中的应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7612086B2 (en) * | 2003-05-16 | 2009-11-03 | Eisai R & D Management Co. Ltd. | JNK inhibitors |
| WO2007076423A2 (en) | 2005-12-22 | 2007-07-05 | Smithkline Beecham Corporation | INHIBITORS OF Akt ACTIVITY |
| WO2007084667A2 (en) * | 2006-01-19 | 2007-07-26 | Osi Pharmaceutical, Inc. | Fused heterobicyclic kinase inhibitors |
| EP1981887A2 (en) * | 2006-02-01 | 2008-10-22 | SmithKline Beecham Corporation | Pyrrolo[2,3,b]pyridine derivatives useful as raf kinase inhibitors |
| GB0617161D0 (en) * | 2006-08-31 | 2006-10-11 | Vernalis R&D Ltd | Enzyme inhibitors |
| WO2008110508A1 (en) * | 2007-03-09 | 2008-09-18 | Glaxo Group Limited | Pyrrolo-pyridine derivatives for the treatment of disorders associated with inappropriate ikk1 activity |
| EA019103B1 (ru) | 2007-03-20 | 2014-01-30 | Кьюрис, Инк. | Конденсированный аминопиридин в качестве ингибиторов hsp90 |
| EP2408772B1 (en) * | 2009-03-19 | 2015-07-01 | Medical Research Council Technology | Compounds |
| GB201008134D0 (en) * | 2010-05-14 | 2010-06-30 | Medical Res Council Technology | Compounds |
| GB201015949D0 (en) * | 2010-09-22 | 2010-11-03 | Medical Res Council Technology | Compounds |
| MX354215B (es) * | 2011-04-05 | 2018-02-19 | Sloan Kettering Inst Cancer Res | Inhibidores de la proteina 90 de choque termico (hsp90). |
| TW201533043A (zh) | 2013-04-18 | 2015-09-01 | Lundbeck & Co As H | 作爲ｌｒｒｋ２抑制劑的芳基吡咯并吡啶衍生化合物 |
-
2014
- 2014-04-08 TW TW103112818A patent/TW201533043A/zh unknown
- 2014-04-14 CN CN201480021665.9A patent/CN105263930B/zh not_active Expired - Fee Related
- 2014-04-14 JP JP2016508109A patent/JP6461097B2/ja not_active Expired - Fee Related
- 2014-04-14 ES ES14720062.0T patent/ES2642204T3/es active Active
- 2014-04-14 EP EP14720062.0A patent/EP2986608B1/en active Active
- 2014-04-14 US US14/777,805 patent/US9499542B2/en not_active Expired - Fee Related
- 2014-04-14 WO PCT/EP2014/057482 patent/WO2014170248A1/en not_active Ceased
- 2014-04-16 AR ARP140101626A patent/AR095885A1/es unknown
- 2014-04-17 US US14/255,317 patent/US20140315901A1/en not_active Abandoned
-
2016
- 2016-10-07 US US15/288,255 patent/US9675594B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP6461097B2 (ja) | 2019-01-30 |
| TW201533043A (zh) | 2015-09-01 |
| AR095885A1 (es) | 2015-11-18 |
| EP2986608B1 (en) | 2017-08-23 |
| US9675594B2 (en) | 2017-06-13 |
| CN105263930B (zh) | 2017-06-09 |
| WO2014170248A1 (en) | 2014-10-23 |
| US9499542B2 (en) | 2016-11-22 |
| HK1222387A1 (en) | 2017-06-30 |
| US20160102089A1 (en) | 2016-04-14 |
| US20140315901A1 (en) | 2014-10-23 |
| EP2986608A1 (en) | 2016-02-24 |
| CN105263930A (zh) | 2016-01-20 |
| JP2016516791A (ja) | 2016-06-09 |
| US20170020850A1 (en) | 2017-01-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6461097B2 (ja) | Ｌｒｒｋ２阻害剤としてのアリールピロロピリジン誘導化合物 | |
| AU2019203122B2 (en) | Cot modulators and methods of use thereof | |
| ES3032327T3 (en) | Compounds and uses thereof | |
| ES2785498T3 (es) | Ftalazinonas e isoquinolinonas como inhibidores de ROCK | |
| ES2316546T3 (es) | 2-arilamino-pirimidinas para el tratamiento de trastornos asociados a gsk3. | |
| JP6496301B2 (ja) | Ｒａｓ／ｒａｆ／ｍｅｋ／ｅｒｋ経路およびｐｉ３ｋ／ａｋｔ／ｐｔｅｎ／ｍｔｏｒ経路の二重阻害剤としてのキナゾリンおよびアザキナゾリン | |
| US10793575B2 (en) | Oxoisoquinoline derivatives | |
| ES3043183T3 (en) | Compounds and uses thereof | |
| TW201825472A (zh) | 新穎化合物類 | |
| ES3056661T3 (en) | Quinoline derivatives as protein kinase inhibitors | |
| CN107072985A (zh) | 治疗性抑制化合物 | |
| BR112015010102B1 (pt) | Composto heterocíclico substituído por amida e composição farmacêutica que o compreende | |
| US20240150343A1 (en) | Compound having brd4 inhibitory activity, preparation method therefor and use thereof | |
| WO2022006386A1 (en) | Alkyne quinazoline derivatives as inhibitors of erbb2 | |
| US20230391769A1 (en) | Substituted heterocyclic compounds and therapeutic uses thereof | |
| TW202317544A (zh) | 吡啶酮mk2抑制劑及其用途 | |
| US20240116921A1 (en) | Lactam (hetero)arylfusedpyrimidine derivatives as inhibitors of erbb2 | |
| US20250011327A1 (en) | Tricyclic compounds | |
| CN103613591B (zh) | 作为cMet抑制剂的化合物及其制备方法和用途 | |
| KR20210097161A (ko) | 헤모글로빈 조절제로서의 피라졸 | |
| JP2019001715A (ja) | 三環性化合物 | |
| CN114133394B (zh) | 一种选择性针对细胞周期依赖性激酶12活性的化合物、制备方法及医药用途 | |
| US20240391931A1 (en) | Tricyclic fused pyrimidine compounds for use as her2 inhibitors | |
| ES3046239T3 (en) | Novel 1h-pyrazolopyridine derivative and pharmaceutical composition containing same | |
| HK40107306A (en) | Pyridinone mk2 inhibitors and uses thereof |